Improving outcomes for patients with glioblastoma by targeting the DNA damage response

For the Microsoft Teams link, please contact

Anthony Chalmers is Chair of Clinical Oncology at the University of Glasgow and Director of the CRUK Glasgow RadNet Centre. His clinical practice at the Beatson West of Scotland Cancer Centre is devoted to the treatment of patients with brain tumours, and he runs the Translational Radiation Biology laboratory in the Institute for Cancer Sciences. His main research ambition is to improve outcomes for patients with glioblastoma by combining radiotherapy with drug therapies that target the DNA damage response, but his interests and activities extend across other cancer types.

He is Chief Investigator for a portfolio of early phase clinical trials evaluating the PARP inhibitor olaparib and the ATM inhibitor AZD1390 in combination with radiotherapy and/or chemotherapy in the treatment of glioblastoma, and is working with other UK investigators to build novel clinical trial platforms including BRAIN-MATRIX and the CONCORDE study in non-small cell lung cancer.

From 2016 to 2019 he was Chair of the UK’s Clinical and Translational Radiotherapy Research Working Group (CTRad) and in 2020 he co-founded the CRUK RadNet Radiotherapy-Drug Combinations Working Group. Currently an Executive Board Member of the European Association for Neuro-Oncology (EANO), he sits on the Radiobiology Committee of the European Society for Therapeutic Radiation Oncology (ESTRO) and is Chair of the Scottish Radiotherapy Research Forum (ScoRRF). In 2020 he was appointed to the Medical Research Council’s Molecular and Cellular Medicine Board.